News & Events about Repligen Corp.
Fool.com Headlines
1month ago
Investors appear to be anticipating an underwhelming first-quarter report from the bioprocessing company.Shares of bioprocessing technology company Repligen (NASDAQ: RGEN) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. That steep decline appears to be connected to the first-quarter ...
Globe Newswire
4 months ago
Martin Madaus
Repligen Appoints Martin Madaus to Board of Directors
WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus. Dr. Madaus brings to the ...
Globe Newswire
4 months ago
Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. ESTWALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, ...
Repligen (NASDAQ:RGEN Get Rating) had its price objective lowered by investment analysts at SVB Leerink from $230.00 to $200.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an outperform rating on the biotechnology companys stock. SVB ...
Globe Newswire
5 months ago
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 41stAnnual J.P. Morgan Healthcare conference being held January 9-12 in San Francisco. Tony J. ...